Section Arrow
Quote
BMEA.NASDAQ
- Biomea Fusion
Quotes are at least 15-min delayed:2026/04/18 01:31 EDT
Regular Hours
Last
 2.21
+0.28 (+14.51%)
Day High 
2.22 
Prev. Close
1.93 
1-M High
2 
Volume 
3.44M 
Bid
2.18
Ask
2.21
Day Low
1.9501 
Open
1.98 
1-M Low
1.07 
Market Cap 
139.54M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.82 
20-SMA 1.54 
50-SMA 1.41 
52-W High 3.08 
52-W Low 0.8719 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.18/-1.46
Enterprise Value
139.67M
Balance Sheet
Book Value Per Share
0.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.2572+0.0049+1.94%0.09PE
PBMPsyence Biomedical Ltd.7.6+1.73+29.47%-- 
GERNGeron Corp1.68-0.01-0.59%-- 
IBRXImmunityBio7.7+0.45+6.21%-- 
ADMAADMA Biologics11.01+0.27+2.51%17.92PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.